[老年人的抗胆固醇负担]
1Farmacéutica comunitaria en Ferrol (La Coruña) España.
Farmaceuticos comunitarios
|January 20, 2025
概括
高抗胆固醇药物负担在老年患者中很常见,可能导致身体和认知问题. 处方者应考虑这种负担,以减轻老年人的不良影响.
科学领域:
- 老年学是一门学科.
- 临床药理学 临床药理学
- 神经科学是一个神经科学.
背景情况:
- 抗胆固醇药物经常被处方用于诸如帕金森病,抑郁症和过敏等常见疾病.
- 以前的研究表明,高抗胆固醇负担与多种药物治疗的老年人中不良的身体和认知结果之间存在联系.
研究的目的:
- 审查有关高抗胆固醇负担与老年人功能衰退之间的关系的现有假设.
- 调查抗胆固醇负担与多种药物治疗的老年人认知和身体功能障碍之间的联系.
主要方法:
- 对抗胆固醇负担及其影响的当前文献进行了全面的文献综述.
- 设计并实施了一项涉及70岁以上多种药物治疗患者的横截面研究.
- 计算了每个患者的药物治疗方案的抗胆固醇负担,并评估认知和身体功能障碍.
主要成果:
- 在老年患者中发现抗胆固醇药物处方的高患病率.
- 观察到高抗胆固醇负担与不良反应发生之间的相关性.
- 发现高抗胆固醇负担可能会导致老年人的身体和认知恶化.
结论:
- 这项研究强调了在老年人群中使用抗胆固醇药物的显著流行率.
- 结果强调了抗胆固醇负担对老年人身体和认知健康的潜在负面影响.
- 强调临床医生在对老年患者的处方过程中需要考虑抗胆固醇负担.
相关概念视频
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
613
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
613
Anticholinesterase Agents: Poisoning and Treatment
780
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
780
Cholinergic Antagonists: Pharmacological Actions
820
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
820
Cholinergic Antagonists: Therapeutic Uses
707
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
707
Parkinson's Disease: Treatment
202
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
202
Cholinergic Antagonists: Pharmacokinetics
407
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
407


